Samina Hamied, 

Whenever there has been a global health crisis—bird flu, swine flu, or the Anthrax scare—Cipla has taken the lead by making available affordable life-saving medicines. And its response to the Covid-19 pandemic has been no different. The ₹17,000-crore pharmaceutical major brought to market antivirals remdesivir and favipiravir, and the immunosuppressive drug tocilizumab, for the treatment of Covid-19. It also took efforts to ensure that there was fair and equitable access to these drugs across the country, despite varying state-wise lockdown restrictions. It also set up a ₹25-crore fund to support Covid-19 patients, augment the healthcare ecosystem in the country, and sustain communities during the pandemic. Cipla, under Hamied’s leadership, continues to report market-beating growth in its India business. Its branded prescription, trade generics, and consumer healthcare business in the country has collectively grown to $1 billion in revenue, accounting for about 40% of the company’s total revenues. Hamied joined Cipla’s management team in 2011, and has been in the current role since September 2016.